Theravance Biopharma (TBPH)

• Market cap: $438M
• 1 day: -1.66%
• 5 days: -5.04%
• 1 month: -3.17%
• 3 months: -4.83%
• 6 months: 9.38%
• Year to date: -4.53%
• 1 year: -4.63%
• 5 years: -61.21%
• 10 years: -48.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Employees: 99

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more call options, than puts

Call options by funds: $6K | Put options by funds: $3K

53% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 15

30% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 33

14% more capital invested

Capital invested by funds: $371M [Q3] → $422M (+$51.4M) [Q4]

7% more funds holding

Funds holding: 119 [Q3] → 127 (+8) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]

2.35% less ownership

Funds ownership: 94.66% [Q3] → 92.3% (-2.35%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 69% upside
• Avg. target: $15 69% upside
• High target: $15 69% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 0% 1-year accuracy 0 / 19 met price target

69% upside $15

Buy Reiterated

27 Feb 2025